Free tool
FAERS Monitor: Imbruvica
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210563 or its brand name (Imbruvica, Ibrutinib). Reports on generic versions are filed under their own applications.
Reports
80,997
Serious
63,021
78% of reports
Hospitalization
26,987
Death reported
13,832
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death8,652
- off label use6,069
- fatigue4,780
- diarrhoea4,224
- atrial fibrillation3,926
- pneumonia3,291
- contusion2,827
- incorrect dose administered2,779
- fall2,544
- asthenia2,378
- nausea2,331
- arthralgia2,226
- rash2,154
- haemorrhage2,022
- disease progression1,999
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 64 |
| 2014 | 1,286 |
| 2015 | 4,210 |
| 2016 | 4,326 |
| 2017 | 5,376 |
| 2018 | 7,196 |
| 2019 | 8,568 |
| 2020 | 10,342 |
| 2021 | 7,680 |
| 2022 | 13,527 |
| 2023 | 8,225 |
| 2024 | 4,441 |
| 2025 | 3,593 |
| 2026 | 2,158 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,973,162 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| atrial fibrillationSignal | 3,926 | 10.9 | 10.5 | 33,899 |
| contusionSignal | 2,827 | 7.8 | 7.5 | 16,403 |
| haemorrhageSignal | 2,022 | 5.1 | 4.9 | 6,569 |
| disease progressionSignal | 1,999 | 4.4 | 4.3 | 5,274 |
| incorrect dose administeredSignal | 2,779 | 3.2 | 3.1 | 4,165 |
| pneumoniaSignal | 3,291 | 2.7 | 2.6 | 3,415 |
| deathSignal | 8,652 | 2.6 | 2.6 | 8,976 |
| fall | 2,544 | 2.0 | 1.9 | 1,267 |
| off label use | 6,069 | 1.8 | 1.8 | 2,259 |
| diarrhoea | 4,224 | 1.7 | 1.7 | 1,258 |
| asthenia | 2,378 | 1.6 | 1.6 | 610 |
| fatigue | 4,780 | 1.6 | 1.6 | 1,103 |
| arthralgia | 2,226 | 1.4 | 1.3 | 249 |
| rash | 2,154 | 1.3 | 1.2 | 138 |
| nausea | 2,331 | 0.8 | 0.7 | 176 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.